You are here

Vaccines

Primary tabs

Information on vaccines to counter Ebola and other diseases

The Mission of this group is to follow the development of vaccines and other medications to counter Ebola and other diseases.

Members

Kathy Gilbeaux mdmcdonald MDMcDonald_me_com mike kraft

Email address for group

vaccines_global@m.resiliencesystem.org

WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use

WHO listed two versions of the AstraZeneca/Oxford COVID-19 vaccine for emergency use, giving the green light for these vaccines to be rolled out globally through COVAX. The vaccines are produced by AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India.

Problem, Solution, SitRep, or ?: 

ANALYSIS" The need for global access to COVID-19 vaccines: production, affordability, allocation, and deployment

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00306-8/fulltext

The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity. Regulators in numerous countries have authorised or approved COVID-19 vaccines for human use, with more expected to be licensed in 2021. Yet having licensed vaccines is not enough to achieve global control of COVID-19: they also need to be produced at scale, priced affordably, allocated globally so that they are available where needed, and widely deployed in local communities.

In this Health Policy paper, we review potential challenges to success in each of these dimensions and discuss policy implications. To guide our review, we developed a dashboard to highlight key characteristics of 26 leading vaccine candidates, including efficacy levels, dosing regimens, storage requirements, prices, production capacities in 2021, and stocks reserved for low-income and middle-income countries. We use a traffic-light system to signal the potential contributions of each candidate to achieving global vaccine immunity, highlighting important trade-offs that policy makers need to consider when developing and implementing vaccination programmes. ...

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Shortage of vaccines prompt some reluctance to establish more vaccination sites.

OKLAHOMA CITY (AP) — The Biden administration’s plan to open 100 vaccination sites by the end of the month was initially embraced by governors and health officials, who considered it a much needed lifeline to get more Americans inoculated against the coronavirus.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Covid-19 Vaccines have become a diplomacy tool in third world

NEW DELHI — India, the unmatched vaccine manufacturing power, is giving away millions of doses to neighbors friendly and estranged. It is trying to counter China, which has made doling out shots a central plank of its foreign relations. And the United Arab Emirates, drawing on its oil riches, is buying jabs on behalf of its allies.

The coronavirus vaccine — one of the world’s most in-demand commodities — has become a new currency for international diplomacy.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Although more vaccines are on their way, logistical hurdles remain

WASHINGTON — The Biden administration said Thursday it had secured 200 million more doses of coronavirus vaccines, enough to inoculate every American adult, but President Biden warned that logistical hurdles would most likely mean that many Americans will still not have been vaccinated by the end of the summer.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

howdy folks
Page loaded in 0.801 seconds.